These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 24608202)

  • 1. Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer.
    Han X; Diao L; Xu Y; Xue W; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Ann Oncol; 2014 Jun; 25(6):1158-64. PubMed ID: 24608202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity.
    Beauclair S; Formento P; Fischel JL; Lescaut W; Largillier R; Chamorey E; Hofman P; Ferrero JM; Pagès G; Milano G
    Ann Oncol; 2007 Aug; 18(8):1335-41. PubMed ID: 17693647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Tobacco Use, Alcohol Consumption and HER2 Polymorphisms With Response to Trastuzumab in HER2-Positive Breast Cancer Patients.
    Furrer D; Jacob S; Michaud A; Provencher L; Lemieux J; Diorio C
    Clin Breast Cancer; 2018 Aug; 18(4):e687-e694. PubMed ID: 29275864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer.
    Nelson SE; Gould MN; Hampton JM; Trentham-Dietz A
    Breast Cancer Res; 2005; 7(3):R357-64. PubMed ID: 15987431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab.
    Lemieux J; Diorio C; Côté MA; Provencher L; Barabé F; Jacob S; St-Pierre C; Demers E; Tremblay-Lemay R; Nadeau-Larochelle C; Michaud A; Laflamme C
    Anticancer Res; 2013 Jun; 33(6):2569-76. PubMed ID: 23749910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in early-stage HER2 positive breast cancer.
    Vazdar L; Gabrić ID; Kruljac I; Pintarić H; Šeparović R; Kirigin Biloš LS; Pavlović M; Tečić Vuger A; Štefanović M
    Sci Rep; 2021 Jul; 11(1):14395. PubMed ID: 34257352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case-control study of the HER2 Ile655Val polymorphism and risk of breast cancer in Taiwan.
    Lee SC; Hou MF; Hsieh PC; Wu SH; Hou LA; Ma H; Tsai SM; Tsai LY
    Clin Biochem; 2008 Feb; 41(3):121-5. PubMed ID: 18062925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L; Eiermann W; Semiglazov V; Lluch A; Tjulandin S; Zambetti M; Moliterni A; Vazquez F; Byakhov MJ; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Magazzù D; Heinzmann D; Steinseifer J; Valagussa P; Baselga J
    Lancet Oncol; 2014 May; 15(6):640-7. PubMed ID: 24657003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer.
    Lee HJ; Seo AN; Kim EJ; Jang MH; Suh KJ; Ryu HS; Kim YJ; Kim JH; Im SA; Gong G; Jung KH; Park IA; Park SY
    Am J Clin Pathol; 2014 Dec; 142(6):755-66. PubMed ID: 25389328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer.
    Dieci MV; Conte P; Bisagni G; Brandes AA; Frassoldati A; Cavanna L; Musolino A; Giotta F; Rimanti A; Garrone O; Bertone E; Cagossi K; Sarti S; Ferro A; Piacentini F; Maiorana A; Orvieto E; Sanders M; Miglietta F; Balduzzi S; D'Amico R; Guarneri V
    Ann Oncol; 2019 Mar; 30(3):418-423. PubMed ID: 30657852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.
    Loi S; Michiels S; Lambrechts D; Fumagalli D; Claes B; Kellokumpu-Lehtinen PL; Bono P; Kataja V; Piccart MJ; Joensuu H; Sotiriou C
    J Natl Cancer Inst; 2013 Jul; 105(13):960-7. PubMed ID: 23739063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABCB1 C3435T gene polymorphism as a potential biomarker of clinical outcomes in HER2-positive breast cancer patients.
    Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Segura-Pérez AM; Chamorro-Santos C; Vergara-Alcaide E; Castillo-Portellano L; Calleja-Hernández MÁ
    Pharmacol Res; 2016 Jun; 108():111-118. PubMed ID: 27137881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).
    Untch M; von Minckwitz G; Gerber B; Schem C; Rezai M; Fasching PA; Tesch H; Eggemann H; Hanusch C; Huober J; Solbach C; Jackisch C; Kunz G; Blohmer JU; Hauschild M; Fehm T; Nekljudova V; Loibl S;
    J Clin Oncol; 2018 May; 36(13):1308-1316. PubMed ID: 29543566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-treatment hormonal receptor status and Ki67 index predict pathologic complete response to neoadjuvant trastuzumab/taxanes but not disease-free survival in HER2-positive breast cancer patients.
    Zhang GC; Qian XK; Guo ZB; Ren CY; Yao M; Li XR; Wang K; Zu J; Liao N
    Med Oncol; 2012 Dec; 29(5):3222-31. PubMed ID: 22547076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab.
    Lee HJ; Kim JY; Park SY; Park IA; Song IH; Yu JH; Ahn JH; Gong G
    Am J Clin Pathol; 2015 Oct; 144(4):570-8. PubMed ID: 26386078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
    Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
    Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The erbB2/HER2/neu receptor polymorphism Ile655Val and breast cancer risk.
    Cox DG; Hankinson SE; Hunter DJ
    Pharmacogenet Genomics; 2005 Jul; 15(7):447-50. PubMed ID: 15970791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab and survival of patients with metastatic breast cancer.
    Kast K; Schoffer O; Link T; Forberger A; Petzold A; Niedostatek A; Werner C; Klug SJ; Werner A; Gatzweiler A; Richter B; Baretton G; Wimberger P
    Arch Gynecol Obstet; 2017 Aug; 296(2):303-312. PubMed ID: 28616827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.
    Perez EA; Jenkins RB; Dueck AC; Wiktor AE; Bedroske PP; Anderson SK; Ketterling RP; Sukov WR; Kanehira K; Chen B; Geiger XJ; Andorfer CA; McCullough AE; Davidson NE; Martino S; Sledge GW; Kaufman PA; Kutteh LA; Gralow JR; Harris LN; Ingle JN; Lingle WL; Reinholz MM
    J Clin Oncol; 2011 Feb; 29(6):651-9. PubMed ID: 21245420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.